Presented to a non-profit, academic, or research organization that made the greatest advancement in, and/or the greatest overall contribution to, the California life sciences sector in the prior year.
MedTech Color is a 501(c)(3) organization aiming to advance the representation of persons of color in the medical device industry. We are a destination and resource for professional development, thought leadership, and strategies to increase the number of underrepresented executives who enter, stay, and contribute to the industry.
Based in Los Angeles, MedTech Innovator is the largest medical technology accelerator in the world. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming healthcare. Since 2013, MedTech Innovator has graduated 421 companies that have gone on to raise $5.8B in follow-on funding and bring 140 life changing innovations to market.
Stanford Byers Center for Biodesign
Co-founded in 2001 by Paul Yock and Josh Makower, the Stanford Byers Center for Biodesign is committed to advancing health outcomes and equity through innovation education, translation and policy. To date, over 7.6 million people have been helped by technologies invented at Stanford Biodesign, and the biodesign innovation process has been widely adopted around the world.
SPARK at Stanford Translational Research Program
Since 2006, the SPARK at Stanford translational research program has advanced 159 promising biomedical discoveries to benefit patients and society. Through SPARK’s unique environment of mentoring and partnership with volunteer industry experts and a comprehensive educational ecosystem, SPARK projects translated into 48 startups, 23 licenses to existing companies, 21 clinical trials within Stanford, and over $1 billion in follow-on funding.
Presented to a biotech or pharmaceutical company that made the greatest advancement in, and/or the greatest overall contribution to, the California life sciences sector in the prior year.
Alector is a clinical-stage biotech company pioneering immuno-neurology and immuno-oncology, novel therapeutic approaches for treating neurodegeneration and cancer. The approach harnesses the central and peripheral immune systems to target immune dysfunction to treat disease. With a one-of-a-kind portfolio of therapeutic candidates, we hope to leverage innate immunity to launch ground-breaking medicines at the intersection of immunology and human genetics.
Coherus is a biopharmaceutical company focused on expanding patient access to life-saving therapies. Building on our success with biosimilars, Coherus is developing a novel immuno-oncology portfolio, exploring combinations with novel targets with the goal of extending patient survival. Named as one of the fastest growing companies in the U.S. by Deloitte (2021) and Financial Times (2022), Coherus is proud to further its legacy.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. Founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
Presented to medical device, digital health, or medical diagnostic companies that made the greatest advancement in, and/or the greatest overall contribution to, the California life sciences sector in the prior year.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
Eko is a digital health company applying machine learning in the fight against heart and lung disease with AI-powered smart stethoscopes. Its FDA-cleared technology is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect disease earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Learn more at ekohealth.com.
Imperative Care is developing life-saving solutions that address urgent needs from onset through recovery for patients suffering from vascular diseases such as stroke. Empowering doctors and patients with innovative tools designed to improve patient outcomes, the company has three 510(k) cleared product platforms, as well as an expansive technology development pipeline.
RefleXion transforms radiopharmaceuticals from diagnosing cancer to actively guiding delivery of external-beam radiotherapy by leveraging individual tumor biology. Designated an FDA Breakthrough Device, RefleXion’s biology-guided radiotherapy automates targeting and motion management to overcome long-standing barriers preventing definitive radiotherapy for metastatic disease. In strategic collaborations with radiopharmaceutical companies, RefleXion will co-develop and co-commercialize disease-specific radiotracers for difficult to treat late-stage cancers.
Shockwave Medical is focused on developing products intended to transform the way calcified cardiovascular disease is treated. The company is establishing a new standard of care through its proprietary local delivery of sonic pressure waves to breakup calcified plaque, which the company pioneered as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to improve patient outcomes.
Presented to an emerging life sciences company whose achievement during the preceding year shows potential to make significant contributions to the future of the life sciences. This award highlights up-and-coming California-based innovators who are making strides towards transforming the life sciences landscape.
Alladapt is developing a novel immunotherapy that works by desensitizing patients allergic to one or multiple foods simultaneously to mitigate risk of severe, life-threatening allergic reactions. Alladapt was co-founded by Dr. Kari Nadeau, a renowned food allergist, and former 23andMe exec, Ashley Dombkowski who serves as Alladapt’s CEO. They expect data from the Harmony Phase 1/2 study in early 2023.
BridGene Biosciences focuses on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases. To achieve this goal, BridGene developed a proprietary chemoproteomics based platform, IMTAC™, which enables the screening of small molecules against all the proteins in live cells to discover drug candidates for previous undruggable targets that cause diseases.
Caption Health has developed the AI platform that enables heart ultrasound access for early disease detection – when there is the highest potential for impact. The company’s Caption Care services offer health providers, payers, and value-based care organizations convenient and cost-effective echos for their members, leveraging its Caption AI technology platform
Fauna Bio is unlocking the secrets of animal genomics to improve human health. With the world’s largest and most diverse dataset of highly adapted animals, cutting-edge computational and genomics tools, and an expert multidisciplinary team, Fauna Bio is changing the paradigm of drug discovery and identifying novel treatments for wide-ranging conditions, including pulmonary disease, fibrosis, obesity and neurodegenerative diseases.
Presented to an individual or individuals who demonstrate their commitment to make the world a better place by employing new, innovative business models and practices in support of their team and the life sciences. They will be recognized for overall achievement in and contribution to the California life sciences community, ability to create and execute on a vision, mentorship of future leaders, notable track record of value-creation, and support of initiatives that impact the patients we serve.
Paul J. Hastings
Nkarta CEO and BIO Chair Paul Hastings is a patient turned innovator, channeling unique perspectives to reset biopharma’s relationship with patients and champion biotechnology innovation. Hastings chairs Youth Rally advocacy organization and helped launch the Biotech Social Contract, the BIO Patient Advocacy Summit, BIO Equality, and OUTbio Bay Area. At Nkarta, he is spearheading developing NK cell therapies for cancer.
An early pioneer in the high-throughput synthesis and sequencing of DNA, Emily Leproust, Ph.D., is disrupting markets to enable the exponential growth of DNA-based applications across chemicals/materials, diagnostics, therapeutics, food and digital data storage. She co-founded Twist Bioscience and as CEO has grown Twist from three to over 1 thousand employees with a global presence.
Dr. Love joined GBT in 2014 to address the long-standing needs of underserved patient communities, starting with sickle cell disease. Previously he was head of R&D and technical operations at Onyx Pharmaceuticals, served as CEO of Nuvelo, and held senior roles at Theravance and Genentech. Dr. Love currently serves on the boards of SeaGen and Royalty Pharma, is vice chair of board of BIO, and a founding board member of Life Science Cares Bay Area. He holds a B.A. in molecular biology from Haverford College, an M.D. from Yale Medical School and completed his training at Massachusetts General Hospital.
Frederic H. Moll, M.D., Hon. FRCS serves as Chief Development Officer of Johnson & Johnson’s Digital Surgery Group. Prior to Johnson & Johnson, Dr. Moll founded Auris Health, Inc., and in 1995, founded Intuitive Surgical, Inc. (Nasdaq: ISRG). Dr. Moll earned a M.D. from the University of Washington, School of Medicine, a M.S. degree in Management from Stanford University’s Sloan Program, and a B.A. degree from the University of California at Berkeley.
Irv Weissman discovered blood stem cells, did clinical trials changing survival of widespread breast cancer from 0 to 33% [25 years]. Blood stem cells cure genetic blood diseases and induce acceptance of organs from stem cell donors. He discovered ‘don’t eat me’ signals that prevent macrophages from eliminating leukemias and lymphomas, and brought antibodies that inhibit them to successful trials.